Patent classifications
A61K40/4236
ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
An anti-EGFRviii antibody, a polypeptide, a cell expressing the polypeptide, a pharmaceutical composition containing the cell, a method for producing the cell, and a polynucleotide or a vector including a nucleotide sequence encoding the polypeptide.
ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19
The present disclosure provides an isolated immune cell which expresses a receptor, interleukin-7, and chemokine (C-C motif) ligand 19.
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
The present invention is generally directed to a colorectal (CRC) cell atlas that provides methods of predicting outcomes of cancer patients and therapeutic targets for treating patients in need thereof. The atlas may be used to predict a response to immunotherapy, in particular checkpoint blockade therapy and adoptive cell transfer. Disclosed herein are previously unidentified gene programs in tumors that can be used to predict response and provide for therapeutic targets that can be used to shift a tumor to a responsive phenotype.
CHIMERIC ANTIGEN RECEPTOR, CELL EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION INCLUDING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR INCLUDING NUCLEOTIDE SEQUENCE ENCODING SAID CHIMERIC ANTIGEN RECEPTOR
The present disclosure provides a chimeric antigen receptor including a target antigen-binding domain, a transmembrane domain, and a signal transduction domain.
COMPOSITIONS AND METHODS FOR MAINTAINING A CCL3/CCL4 AND CCR5 INTERACTION PROGRAM EXPRESSED DURING TUMOR PROGRESSION
Embodiments disclosed herein provide compositions for increasing CCL3 and/or CCL4 interactions with CCR5 and/or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocytes/macrophages that change during tumor progression from small to medium to large tumors. The ligands CCL3 and CCL4 are expressed in a specific subset of T cells (CD8+ PD-1+ TIM3+ T cells). The receptors CCR5 and CCR1 are expressed in inflammatory monocytes/macrophages. Modulation or maintenance of these interactions can allow enhanced immune responses for treating cancer, as well as for vaccination.
Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.
Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.
Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.